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Abstract
Background: 99mTc-mercaptoacetyl-triglycine (99mTc-MAG3) has been used for
dynamic renal imaging since about 30 years. Free pertechnetate (99mTcO4), colloidal
99mTc ((99mTcO2)n),
99mTc-tartrate (precursor), precomplexes (99mTc-(MAG3)x) and
lipophilic 99mTc-MAG2 are the main radiochemical impurities that may occur in the
preparation. The total amount of these impurities has to be identified before release
of the product for patient administration to guarantee patient safety and good image
quality. The European Pharmacopoeia suggests a method based on high-pressure liquid
chromatography analysis in combination with a paper chromatography. This analytical
method is time consuming, expensive and requires specially trained technicians. As a
consequence, it is not widely applied in nuclear medicine radiopharmacies.
Results: We developed a simple method for radiochemical purity testing of 99mTc-MAG3.
The method is based on thin layer chromatography with two strips to be developed in
parallel. Method validation was carried out in comparison to the official methods of the
companies and to the European Pharmacopoeia method. It was tested on specificity,
accuracy, robustness and precision.
Conclusion: The proposed method is able to identify and quantify the sum of all
impurities occurring in the preparation, respecting the acceptance criteria for the
radiochemical purity defined by the official methods. Hydrophilic and lipophilic
compounds are identified separately and results are obtained within less than
20 minutes. Our method is simple, cost effective, fast and is suitable for employing
dose calibrators or radiometric scanners.
Keywords: Radiopharmaceutical Quality Control, 99mTc-MAG3, Radiochemical
Purity, Thin Layer Chromatography
Background
In the early 80’s, 99mTc-MAG3 was introduced as a new dynamic renal imaging agent
(e.g. (Fritzberg et al., 1986; Taylor et al., 1987; Taylor et al., 1987; Brandau et al., 1988;
Bormann et al., 1995)). Today, the preparation is commonly applied in nuclear medi-
cine. For the preparation of 99mTc-MAG3 commercial sterile kits are available in form
of a lyophilized pharmaceutical product. The labeled 99mTc-MAG3 is obtained by add-
ing sodium pertechnetate from a 99mTc radionuclide generator (e.g. (van Hemert et al.,
2005; Nosco et al., 1993; Seetharaman et al., 2006; Chen et al., 1993; Package insert for
Technescan MAG3. Mallinckrodt Suisse SA, 2003; Package insert for ROTOP-MAG-3
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Kit. Heider AG, 2006; Package insert for Technescan MAG3. Mallinckrodt Suisse SA,
2015)). Specific biodistribution of 99mTc-MAG3 is crucial for the patient safety and
image quality and the radiochemical purity (RCP) of the radiopharmaceutical has to be
guaranteed (Fritzberg et al., 1986; Brandau et al., 1988). Radiochemical impurities may
lead to imprecise interpretation of diagnostics and can cause unnecessary patient and
operator irradiation if the examination has to be repeated. Therefore, a liable quality
control (QC) method quantifying the radiochemical impurities occurring in the radio-
pharmaceutical preparation is indispensable to release the product for patient
administration.
Potentially occurring radiochemical impurities in the preparation of 99mTc-MAG3 are
free pertechnetate (99mTcO4), colloidal technetium ((
99mTcO2)n),
99mTc-tartrate (precur-
sor), precomplexes (99mTc-(MAG3)x) and
99mTc-MAG2 (van Hemert et al., 2005;
Nosco et al., 1993; Seetharaman et al., 2006; Chen et al., 1993; Package insert for
Technescan MAG3. Mallinckrodt Suisse SA, 2003; Package insert for ROTOP-MAG-3
Kit. Heider AG, 2006; Package insert for Technescan MAG3. Mallinckrodt Suisse SA,
2015). The European Pharmacopoeia (Ph.Eur.) method for the quality control of the
99mTc-MAG3 preparation separates and quantifies the hydrophilic components
(99mTc-tartrate, 99mTcO4,
99mTc-(MAG3)x,
99mTc-MAG3) and the lipophilic compo-
nents (mainly 99mTc-MAG2) by high-pressure liquid chromatography (HPLC) analysis
(European Pharmacopoeia Edition 7.0, 2008). (99mTcO2)n is analyzed separately by
paper chromatography (PC) likewise described in the Ph.Eur. Fig. 1 gives an overview
of an HPLC analysis performed as described in the Ph.Eur. Hydrophilic (< 4 min) and
lipophilic (> 6 min) components are separated from 99mTc-MAG3 (main peak) and can
be easily quantified to obtain the RCP.
HPCL analysis is not optimal for quality control of radiopharmaceutical preparations
in clinical settings, as the necessary infrastructure is usually not available in nuclear
Fig. 1 Example chromatogram of Ph.Eur. HPLC analysis of 99mTc-MAG3. Hydrophilic compounds occur < 4.0
minutes, 99mTc-MAG3 is identified at about 4.5 minutes, lipophilic compounds are attributed to the region
> 6.0 minute. 99mTc-MAG2 and 99mTcO4 are the main impurities.
99mTc-tartrate elutes as the first peak followed
by small peaks of precomplexes
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medicine departments due to high costs and space limitations. Easy and fast methods
based on thin layer (TLC) or paper chromatography are preferable. As a result, regard-
less of its accuracy, the Ph.Eur. method for the quality control of 99mTc-MAG3 prepa-
rations is not widely applied in nuclear medicine centers.
To overcome this problem in daily practice, an alternative method for RCP testing
based on solid-phase extraction (SPE method with SEP-PAK C18 columns) was developed
by the company and accepted by the Swiss authorities for the quality control (Package in-
sert for Technescan MAG3. Mallinckrodt Suisse SA, 2003). Interestingly, we found
disagreement between the suggested method in Switzerland compared to other countries.
The by the corresponding competent authorities accepted methods differ between the
US, the EU and Switzerland and the acceptance criteria deviate from the specifications de-
fined by the Ph.Eur. Table 1 and 2 summarize the different methods proposed in different
countries for the two existing formulations of MAG3, Mallinckrodt Technescan MAG3
(table 1) and MAG3 from ROTOP MAG3 kit (table 2). The total amount of the RCP
value varies importantly. TLC and SPE methods accept lower RCP values than the RCP
based on the Ph.Eur.
The Swiss method of Mallinckrodt Swiss SA, in force today (Package insert for
Technescan MAG3. Mallinckrodt Suisse SA, 2015), employs SEP-PAK C18 cartridges
to separate hydrophilic and lipophilic radiochemical impurities. The impurities are
quantified employing a dose calibrator. As accepted by the local authorities, the SPE
method is a valid alternative to the Ph.Eur. method.
Intended to be more user friendly, this method is subject to multiple concerns. Testing
its accuracy in a clinical setting, it was found that the RCP was significantly underesti-
mated, which could result in false negative results (Murray et al., 2000). This does not
only imply inconvenience for the patient and additional costs for the hospital, it also
causes unnecessary radiation exposure of the operators when repeating the labeling and
the QC. Handling the syringe and cartridges results in a close contact to the radioactive
solution for several minutes, this may increase extremity doses. Additionally, results for
RCP using SEP-PAK cartridge based methods were found to be operator dependent due
to the influence of unavoidable variations in elution velocity (Vinberg, 2000; Ponto, 2005;
Millar & Hesslewood, 2004). This may be the reason for the reported differences in accur-
acy found in clinical settings versus validation studies by the kit manufacturers.
Based on these drawbacks with the simplified methods, other techniques coming
back to TLC systems have been suggested by different groups (e.g. (van Hemert et al.,
2005; Nosco et al., 1993; Seetharaman et al., 2006; Chen et al., 1993)). Unfortunately, so
far no ideal results being comparable to specifications of the official methods or the
Ph.Eur. method, including evaluation of all possible impurities could be achieved. Some
of the proposed QC methods are even showing contradictory results (Seetharaman et
al., 2006; Chen et al., 1993).
The two goals of our study were to test the Swiss method in force proposed by the
company and to develop a compliant TLC method easier to perform than the SPE
method. With this new method we want to guarantee identification of all possible im-
purities as detected by the Ph.Eur. HPLC and PC method.
Therefore, in a first study, we tested the hypothesis of RCP variations with variations
in elution velocity (Vinberg, 2000; Ponto, 2005; Millar & Hesslewood, 2004) and we
tested the Swiss SPC in force at the time of the study.
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In the second part of our study, we developed and validated a new two-strip TLC
method, which is fast, easy to perform, operator independent and applicable using a
dose calibrator or TLC scanner, standard equipment of a nuclear medicine department.
The developed method does not require HPLC analysis. Radiopharmaceuticals which
are prepared from authorized kits and generators according to the instructions of the
summary of product characteristics (SPC) are not required to be tested according to
the respective pharmacopoeia monograph. Instead, the quality control methods de-
scribed in the SPC are valid, since they are accepted by the pharmaceutical authority.
Our method was validated based on these criteria. Our new TLC method evolves from
a TLC system suggested by Chen et al. (Chen et al., 1993) but uses ethanol with 10%
water as second solvent. We identified characteristics of all possible impurities by per-
forming individual specificity tests and compared the results with the Ph.Eur. HPLC
and PC measurements.
Different to other studies (Seetharaman et al., 2006; Chen et al., 1993), our specificity
tests allowed us to identify 99mTc-MAG2 as a possible impurity in the 99mTc-MAG3
formulation. In addition, our method permits separation of 99mTc-MAG3 from 99mTc-
tartrate. The method was validated in comparison to the official method in force
suggested by the company and shows good agreement with the RPC obtained by the
Ph.Eur. method. This allows suggesting this method as the standard RCP testing
method in any country. The time required to perform the QC is less than 20 minutes,
which responds well to the needs and time constraints in a small scale radiopharmacy
of a nuclear medicine imaging department.
Methods
99mTc-MAG3 was prepared from Technescan MAG3 kits and an Ultra-Technekow
Mo-99/Tc-99 Generator from Mallinckrodt according to the labeling procedure version
Table 2 RPC testing methods for ROTOP MAG3 kit preparations available in Switzerland, European
countries, the US (Package insert for ROTOP-MAG-3 Kit. Heider AG, 2006; Package insert for
ROTOP-MAG-3 Kit, n.d.-a; Package insert for ROTOP-MAG-3 Kit, n.d.-b) in comparison to the method
of the Ph.Eur. (European Pharmacopoeia Edition 7.0, 2008). Each method requires detection of the
sum of liphophilic and hydrophilic impurities, except for the Rotop method from 2016 (only
available for EU countries) where detection of colloidal 99mTc ((99mTcO2)n) as an individual impurity
is specified and acceptance criteria are set separately
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*Lipophilic impurities are attributed to the SEP-PAK cartridge activity.
**Refers to 99mTc-perchtechnetate in the SPC
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2003 (Package insert for Technescan MAG3. Mallinckrodt Suisse SA, 2003). For the
quality control procedures, ACS grade chemicals, iTLC-SG chromatography strips from
Agilent Technologies and highly purified water were used.
SPE Method
In the first part of this study, liability of the SPC method in force at the time of the
study, applying SEP-PAK C18 cartridges (Package insert for Technescan MAG3.
Mallinckrodt Suisse SA, 2003), was tested. SEP-PAK cartriges used were SEP-PAK C18
Plus Short Cartridge, 360 mg Sorbent per Cartridge, 55-105 μm Particle Size, 50/pk
(WATERS Part.Number WAT020515).
Referring to earlier studies (Chen et al., 1993; Vinberg, 2000; Ponto, 2005), we
tested the robustness of the method at different elution rates of 1.7, 10, 20 and 30
ml/min (no indication for an exact elution rate is mentioned in the SPC (Package
insert for Technescan MAG3. Mallinckrodt Suisse SA, 2003)). Results were com-
pared with results obtained by the Ph.Eur. method. The illustration in Fig. 2
summarizes QC procedure according to the SPC version valid at the time of the
study (Package insert for Technescan MAG3. Mallinckrodt Suisse SA, 2003).
Meanwhile, a new version of the SPC has been approved in 2015 (Package insert
for Technescan MAG3. Mallinckrodt Suisse SA, 2015). The method has been sim-
plified to two different elutions. Unfortunately, there is no indication of how to at-
tribute the individual fractions to the two eluates described in the SPC. Possible
impurities are characterized as hydrophiles (3%) and lipophiles (4%). We can only
assume that eluate 1 and the SEP-PAK C18 cartridge contain the lipo- or hydro-
phile impurities, and that eluate 2 contains the 99mTc-MAG3 (94%), as well as
99mTc-MAG2. 99mTc-MAG2 is not listed as possible impurity by the company. In
the SPC version from 2003 (Package insert for Technescan MAG3. Mallinckrodt
Suisse SA, 2003), the hydrophilic, lipophilic impurities and 99mTc-MAG3 were indi-
vidually eluted, measured and clearly attributed to the different eluates. Therefore,
applying the SPC method of 2003 (Package insert for Technescan MAG3.
Fig. 2 Illustration of Mallinckrodt Pharmaceuticals QC procedure for MAG3 kit (version 2003)
Straub et al. EJNMMI Radiopharmacy and Chemistry  (2018) 3:5 Page 6 of 16
Mallinckrodt Suisse SA, 2003) for our study seems to be more adequate to
guarantee reasonable comparison to other methods as the attribution of the eluates
is clearly described.
New TCL method
The new two-strip TLC method for the routine QC of Mallinckrodt Pharmaceutical
99mTc-MAG3 labeling we developed is based on a first separation on an iTLC-SG chro-
matography paper with a 60:40 % mixture of ethyl acetate and methyl ethyl ketone
(MEK), already mentioned in the literature (Chen et al., 1993), combined with a new
solvent for the second separation on the same type of support, with a 90:10 % ethanol/
water mixture.
Two iTLC-SG strips, each 2 - 2.5 cm wide and 10 cm long, were marked with a pen-
cil at 1.5 cm from the bottom of the strip (“start”) and a second line at 8.5 cm indicat-
ing the solvent front (“front”). The strips were dried at 100°C for 1 hour and stored in a
desiccator with silica gel. The conditioned strips were removed from the desiccator
only prior to use (max. 30 minutes). For the chromatography strip one, a solvent mix-
ture of 6 ml ethyl actetate and 4 ml methyl ethyl ketone (EtAc/MEK, 60:40) was pre-
pared and transferred to the chromatography tank. For strip two, 9 ml of ethanol and 1
ml of distilled water (ETOH/H2O, ratio 90:10) were prepared the same way. The tanks
were left to equilibrate for 10-15 minutes. A QC sample aliquot was applied on each
strip and strips were developed in the corresponding tanks in parallel, until the solvent
front. Strip 1 takes about 5 minutes to develop, strip 2 about 15 minutes. When fin-
ished, strips were immediately dried at room temperature before reading with a TLC
scanner or measuring in a dose calibrator (TLC integration limit and dose calibrator
cutting point at 6 cm from the bottom of the strip).
The RCP was calculated applying the following formula:
RCP %ð Þ ¼ 100%− %impurities strip 1þ%impurities strip 2ð Þ
Where:
%impurities strip 1 ¼ activity top part x 100
activity topþ bottom part ¼ 99mTcO4þ TcMAG2
%impurities strip 2 ¼ activity bottom part x 100
activity topþ bottom part ¼ TcO2ð Þnþ TcTartrateþ Tc MAG3ð Þx
Validation methodology
The results of the new quality control method were validated comparing to HPLC and
PC measurements referring to specifications of the official method in force from the
company (Package insert for Technescan MAG3. Mallinckrodt Suisse SA, 2015) and
the Ph.Eur method (European Pharmacopoeia Edition 7.0, 2008). Validation was
performed following the ICH validation guidelines (International Commission on
Harmonisation, 1996). We tested for specificity, accuracy, limit of detection (LoD), ro-
bustness and precision.
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Specificity
The specificity of the analytical method was tested to sufficiently separate the desired
substance from its possible impurities. We tested specificity for free pertechnetate
(99mTcO4), colloidal ((
99mTcO2)n),
99mTc-tartrate and 99mTc-Mag2 (e.g. (Bormann et al.,
1995; van Hemert et al., 2005; Nosco et al., 1993; Seetharaman et al., 2006; Chen et al.,
1993)). The first three impurities are considered as hydrophilic and 99mTc-Mag2 as a
lipophilic impurity. To test the migration behavior and occurrence of these impurities,
the following reference solutions have been prepared and measured:
Solution 1 (99mTcO4): Saline eluate from generator (approx. 250 MBq/ml); Solution 2
((99mTcO2)n): 0.025 ml of SnCl2 solution (1.7 mg/ml) were added to ca. 500 MBq
99mTcO4 and let to equilibrate (gentle shaking); Solution 3 (
99mTc-Tartrate): 0.5 ml of
Na-K tartrate solution (0.4 g dissolved in 10 ml of highly purified water), 0.025 ml of
tin chloride solution (1.7 mg/ml) and ca. 500 MBq 99mTcO4 were added and let to
equilibrate (gentle shaking). The quantitative formation of 99mTc-tartrate was
confirmed by HPLC analysis; Solution 4 (99mTc-MAG2): 5 mg of S-benzyl-Mag2 (syn-
thesized employing method for 99mTc-MAG3 as described in Brandau et al. (Brandau
et al., 1988)), were dissolved in 5 ml of 1-mM-NaOH at 80 °C for 5 min. A septum vial
was purged with nitrogen gas and 1 ml of MAG2 solution and 1ml of Na-K tartrate so-
lution, 0.025 ml of SnCl2 solution and ca. 500 MBq
99mTcO4 were added. The mixture
was heated at 100 °C for 10 minutes and allowed to cool at room temperature. The
quantitative formation of 99mTc-Mag2 was confirmed by HPLC analysis.
Accuracy
The accuracy was validated by comparing RCP values of our two-strip method with the
Ph.Eur. method (European Pharmacopoeia Edition 7.0, 2008) for the same preparation
of 99mTc-MAG3.
Limit of detection and quantification of impurity limit
The limit of detection was tested by performing linearity tests on our instruments. A
deposited activity of about 1MBq/10 μl was considered as reference value for the quan-
tification of impurities (Package insert for Technescan MAG3. Mallinckrodt Suisse SA,
2003). Based on the criteria set in the SPC (Package insert for Technescan MAG3.
Mallinckrodt Suisse SA, 2003; Package insert for Technescan MAG3. Mallinckrodt
Suisse SA, 2015) and the ones defined in the Ph.Eur. monograph (European
Pharmacopoeia Edition 7.0, 2008), we decided setting the quantitative impurity limit to
3 % impurities per TLC strip to guarantee a RPC of minimum 94%.
Robustness
To test the robustness different spot volumes (QC sample aliquot) and variations in
proportions of the solvent mixtures were applied. Additionally, different batches of
iTLC-SG papers were employed.
Precision: Repeatability and intermediate precision
Repeatability was tested on three different labelings of the same batch production of
99mTc-MAG3 applying identical conditions. Each labeling was measured at three
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different times, making three chromatographic separations. An HPLC measurement
was performed on the same batch. Intermediate precision was tested with different la-
boratories, operators, equipment and days.
Results
SPE Method of the company
As already revealed by other studies (Chen et al., 1993; Murray et al., 2000; Vinberg,
2000; Ponto, 2005; Millar & Hesslewood, 2004), the SPE method for RPC testing sug-
gested by the company (Package insert for Technescan MAG3. Mallinckrodt Suisse SA,
2003) shows varying results and seems to be depending on the elution rate. Our results
confirm an inverse correlation between radiochemical purity and elution rates: the
higher the elution rate, the lower the RCP (table 3 and 4). Elution rates ≥10ml/min re-
sult in RCP values of <95%. Applied elution rates of 1.7, 10, 20 and 30 ml/min (Table
3) compared with Ph.Eur. method (table 4, three analyses done at approximately the
same time points as the SEP-PAK measurements) indicate an increasing trend of
hydrophilic and of lipophilic components with elution rates ≥10ml/min.
New two-strip TLC method
The individual results of the validation criteria and comparison with the method of the
Ph.Eur. (HPLC and PC data) are presented below (the complete validation data can be
found in the tables in the Online Resource 1). The results are expressed with 2 stand-
ard deviations (k = 2) meaning that 95.4% of the results are in the mean values.
Specificity
The specificity was validated with samples of 99mTc-MAG3 preparations and individual
reference solutions of the main impurities, with the exception of pre-complexes, which
are not available as isolated compounds. They are attributed to strip 2. Figure 3 shows
an illustration of each TLC strip. 99mTc-MAG3 stays at the origin for strip 1 and mi-
grates to the solvent front for strip 2 similar as in the method of Chen et al. (Chen et
al., 1993). Colloidal (99mTcO2)n stays at the origin with both solvents.
99mTc-tartrate
stays in the lower part of both strips and is therefore separated from the 99mTc-MAG3
on strip 2. 99mTcO4 and
99mTc-MAG2 migrate to the front of both strips and can be
quantified together as impurities on the upper part of strip 1.
Table 3 Table showing the RCP of 99mTc-MAG3 with the SPE-method, resulting from different
elution rates applied. The cartridge was also measured (not requested in SPC 2003) for quantification
of (99mTcO2)n which is retained on the cartridge
Elution rate Hydrophilic compounds 99mTc- MAG3 Lipophilic compounds (99mTcO2)n(cartridge)
[ml/min] [%] [%] [%] [%]
1.7 2.0 95.8 1.7 0.5
10 4.1 93.8 1.8 0.4
10 3.9 93.3 2.4 0.4
20 8.6 86.6 4.3 0.5
30 8.4 79.8 11.3 0.6
Straub et al. EJNMMI Radiopharmacy and Chemistry  (2018) 3:5 Page 9 of 16
Accuracy
On three consecutive days one batch of 99mTc-MAG3 was prepared and analyzed with
the new TLC and the Ph.Eur. method. Three measurements were done each time and
quantified with the TLC scanner and the dose calibrator. For the three replicates, three
different batches of iTLC sheets were used as part of the robustness validation. No sig-
nificant differences were observed. An HPLC measurement was performed on each
batch and taken as the reference value for accuracy identification. Results for accuracy
are summarized in table 5.
Limit of detection and quantification of impurity limit
A linearity of the dose calibrators and the TLC scanners with low 99mTc activities was
realized for each instrument. The detection limit obtained for our systems is 2 kBq for
Table 4 Results of corresponding HPLC measurements at 3 different time points in comparison
with SPE- method results from table 3. The SPC in force today does not mentioned which
impurities are attributed to the individually eluted fractions on the SEP-PAK columns and the
(99mTcO2)n is not taken into account (not measured).
Hydrophilic compounds 99mTc- MAG3 Lipophilic compounds
[%] [%] [%]
HPLC 1 1.5 97.2 1.3
HPLC 2 0.6 98.0 1.4
HPLC 3 1.1 96.9 2.0
Fig. 3 Illustration of the new two-strip TLC method. On strip one, the 99mTcO4 and
99mTc-MAG2 migrate to
the front, all other components stay at the origin. On strip two, 99mTc-MAG3, 99mTcO4 and
99mTc-MAG2
migrate to the front; the other components stay at the origin (positioned at 40 mm on the TLC scanner)
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the TLC scanner and 10 kBq for the dose calibrator. The impurity limit being fixed at
≤ 3%, an activity of 30 kBq can therefore be quantified and is within the linear range of
measurements.
Robustness
Robustness was tested for proportion in solvent mixtures and deposited sample volume
as well as different batches of iTLC-SG papers. The kit was heated to 70°C only to in-
crease the occurring impurities. No variations based on mixtures were observed, similar
as already observed in Chen et al. (Chen et al., 1993). Table 6 and 7 show the results of
RCP in correlation with modified solvent mixtures for the two strips. We observe no
significant influence on the obtained RCP.
Figure 4 shows the chromatograms for different volumes applied. A small influence
of differences in volume of the QC sample was observed mainly on strip 1. The front
peak of the 99mTc-MAG3 is larger with a bigger sample volume but does still not influ-
ence its interpretation. Volumes of 10, 15, and 20 μl were tested and did not reveal sig-
nificant variation in RCP.
The tests using three different batches of iTLC papers (production years 2013, 2015
and 2016) did not reveal any significant difference in RCP (see Online Resource 1 for
individual results).
Intermediate precision
Different operators, TLC scanners, dose calibrators or days did not significantly influ-
ence the RCP results. We observe a good correlation between references values
Table 5 Comparison of RCP values determined by the new TLC method by scanner or dose
calibrator against the RCP obtained by the Ph.Eur. method (HPLC and PC) taken as reference
(standard deviation k=2)
Ph.Eur. 2-strip method Accuracy
Date Validation (HPLC&PC) TLC Scanner Dose calibrator Difference to Ph.Eur. method
[%] [%] [%] TLC Scanner Dose calibrator
[%] [%]
27.04.2016 No 1 97 96.7 ± 0.8 97.1 ± 0.8 -0.3 0.1
28.04.2016 No 2 96.9 96.7 ± 0.5 97.1 ± 0.8 -0.2 0.2
29.04.2016 No 3 95.8 96.1 ± 0.4 Not measured 0.3 N.A.
29.04.2016 No 4 95.6 ± 0.5 96.1 ± 0.5 -0.2 0.3
Table 6 Results of impurities found applying deviations in solvent mixtures for strip 1
Sample Strip 1: Ratio EtAc/MEK
55:45 60:40 65:35
Impurities (%) Impurities (%) Impurities (%)
Sample 1 6.5 6.1 6.0
Sample 2 6.6 6.5 6.0
Sample 3 6.7 6.4 6.6
Average 6.6 6.3 6.2
STD (k=2) 0.2 0.4 0.6
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(Ph.Eur. method by HPLC and TLC (European Pharmacopoeia Edition 7.0, 2008)) and
our two-strip TLC method (see table 5 and validation data in Online Resource 1).
Discussion
The main goal of our study was to develop a simple and fast TLC method identifiying
the main impurities occurring in the heated formulation of a MAG3 preparation
(Package insert for Technescan MAG3. Mallinckrodt Suisse SA, 2003; Package insert
for Technescan MAG3. Mallinckrodt Suisse SA, 2015). Specifications should at mini-
mum meet the criteria set by the company method in force, and additionally show
good agreement to the Ph.Eur. method. Our review of official methods suggested for
this kit preparation within different countries (US, EU and Switzerland) had revealed
important differences between the methods applied for RCP testing. In table 1 and 2
Table 7 Results of impurities found applying deviations in solvent mixtures for strip 2
Sample Strip 2: Ratio EtOH/H2O
87:13 90:10 93:7
Impurities (%) Impurities (%) Impurities (%)
Sample 1 5.0 5.3 5.5
Sample 2 4.9 5.1 5.3
Sample 3 4.6 5.5 5.0
Average 4.8 5.3 5.3
STD (k=2) 0.4 0.4 0.6
a)
b)
Fig. 4 TLC chromatograms with QC samples applied of 15, 15 and 20 microliters
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we had summarized the official methods of RCP testing for heated and non-heated for-
mulations and compared them to the Ph.Eur. method. We found that specifications for
RCP vary between countries and one of the main impurities, colloidal (99mTcO2)n is
often not measured. Surprisingly, none of the suggested methods is fully compliant
with the Ph.Eur. method. Testing our TLC method with other formulations of MAG3
(non-heated formulation), we found very good agreement between our RCP results and
RCP based on the SPC method (Package insert for ROTOP-MAG-3 Kit. Heider AG,
2006). In comparison to the Ph.Eur. so far unsolved discrepancies remained for the
non-heated formulation.
SPE method
Our tests of the manufacturer SPE method in force with the SEP-PAK cartridges (Pack-
age insert for Technescan MAG3. Mallinckrodt Suisse SA, 2003) show that results
don't comply reliably with the reference method of the Ph.Eur. (European
Pharmacopoeia Edition 7.0, 2008). Specifications for RCP are not compliant with the
Ph.Eur. monograph and the robustness of the method is not optimal due to operator
dependency in elution velocity. Vinberg (Vinberg, 2000) reported 1.5 ml/min as max-
imum flow rate to achieve reliable results with the SPE method, but he did not present
data on higher flow rates. Such a low flow rate is difficult to achieve by manual ma-
nipulation and it prolongs the procedure substantially; therefore, we studied higher flow
rates. Indeed, we found that elution rates ≥10 ml/min applied to the kit did significantly
over estimate the hydrophilic impurities in the preparation and some of the lipophilic
components were wrongly attributed to the 99mTc-MAG3 peak (table 3 and 4). Add-
itionally, different to Murray et al. (Murray et al., 2000), we found that not only the
hydrophilic, but also lipohilic impurities may be over estimated. We conclude that only
an automated elution would guarantee a consistent application of the right elution rate;
done manually, results risk varying importantly and possible radiochemical impurities
cannot be identified satisfyingly. Incomplete information about elution rate and specifi-
cation of the eluates in the SPC make this QC method questionable. Interestingly, its
former version, which is the official version in force in European countries (Package in-
sert for Technescan MAG3, 2015), had included these information. The reasoning to
remove this information in the current version in Switzerland is not clear to us. In
addition, the manipulation of the SEP-PAK columns for performing the QC does not
comply with good radiation safety for the personnel. Due to relatively long handling
time of the radioactive material and close contact to extremities, a higher irradiation
may occur applying the SPE method. The missing information about the attribution of
impurities as well the risk of extremity irradiation make this QC method rather
unattractive and explain why it is not widely applied in the centers.
New TLC method
The main radiochemical impurities of the 99mTc-MAG3 preparations are identified by
our two-strip TLC method, with the possible exception of pre-complexes, which seem
distributed over a wider range on strip 2 resulting in some uncertainty. Nonetheless,
the good correlation between the RCP determination by the Ph.Eur. method (European
Pharmacopoeia Edition 7.0, 2008) and our method indicates that the pre-complexes are
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well taken into account in TLC strip 2 and individual identification is not necessary for
guaranteeing accuracy of this method (table 5). Different to other studies (Seetharaman
et al., 2006; Chen et al., 1993), our specificity test allowed us to confirm 99mTc-MAG2
as a possible impurity in the 99mTc-MAG3 formulation. In addition, our method per-
mits separation of 99mTc-MAG3 from 99mTc-tartrate.
To be compliant with the Ph.Eur. method, we decided to set the impurity limits for
hydrophilic and lipophilic impurities to 3%. Hydrophilic impurities are 99mTc-precom-
plexes, pertechnetate (99mTcO4), colloidal form (
99mTcO2)n and
99mTc-tartrate. The
limit of 3% is justified as results of HPLC measurements (obtained by the Ph.Eur.
method) at different temperature conditions had shown that (99mTcO2)n shows
relatively constant values (always below 1%). The main variation occurs in the 99mTc-
precomplexes, 99mTcO4 and
99mTc-tartrate, the other hydrophilic impurities. Setting the
limit to 3% for the sum of the impurities on strip 2 (99mTc-precomplexes, 99mTc-tartrate
and (99mTcO2)n) enables us to respect the 2% for the colloidal form (
99mTcO2)n. If we
would have more than 2% (99mTcO2)n, the other hydrophilic impurities, are likely to be
increased. To set a total limit of 3% seems therefore justified.
The results of our study confirm the ability of our systems to measure the limit
values of impurities in the case of the chosen activities deposited on a chromatography
paper. The used instruments fulfill our acceptance criteria set (30 kBq) for quantifica-
tion of the impurities. In the case of a very low specific activity, the dose calibrator de-
tection may be used with precaution and the use of a gamma counter or TLC scanner
is recommended. This is not specific to our method, but to any quality control method
of radiopharmaceuticals prepared with low specific activities. Differences in volume of
sample for TLC chromatograms may modify the separation between the compounds.
Too large volumes can widen the peaks and reduce their resolution. The presence of a
large amount of water (the main medium of a 99mTc-MAG3 labeling) may also interfere
with a separation. In our method, the influence of differences in volume is more im-
portant for strip 1 where the majority of the sample is not migrating. The deposited
volume widens the base of the 99mTc-MAG3 peak but no influence on RCP interpret-
ation is observed as the peaks are well separated and there is no risk of wrong attribu-
tion of components (fig. 4). Our results show no significant variations in RCP within
modified solvents mixtures (tables 6 and 7). Generally, we recommend the use of a mi-
cro pipette for the addition of solvents to prevent important variations in volumes.
Conclusion
SPC methods for RCP testing for the two existing formulations of 99mTc-MAG3,
heated (Package insert for Technescan MAG3. Mallinckrodt Suisse SA, 2003; Package
insert for Technescan MAG3. Mallinckrodt Suisse SA, 2015) and non-heated (Package
insert for ROTOP-MAG-3 Kit. Heider AG, 2006) differ and results are not in accord-
ance with the Ph.Eur. specifications. Our new two-strip TLC method, combining two
separations on the same type of support with two different solvent mixtures, has been
found to be adequate for the determination of the RCP of 99mTc-MAG3 (Package insert
for Technescan MAG3. Mallinckrodt Suisse SA, 2003). The RCP obtained by TLC does
not deviate significantly from the reference RCP determined by HPLC and PC follow-
ing the Ph.Eur. method (European Pharmacopoeia Edition 7.0, 2008). The limit value
for the total RCP is identic. This was not the case in former proposed methods where
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some impurities have been excluded and declared as insignificant (Seetharaman et al.,
2006; Chen et al., 1993; Package insert for Technescan MAG3. Mallinckrodt Suisse SA,
2003; Package insert for ROTOP-MAG-3 Kit. Heider AG, 2006; Package insert for
Technescan MAG3. Mallinckrodt Suisse SA, 2015; Package insert for Technescan
MAG3, 2015; Package insert for Technescan MAG3, 2015; Package insert for ROTOP-
MAG-3 Kit, n.d.-a; Package insert for ROTOP-MAG-3 Kit, n.d.-b). The specificity and
accuracy of our method have been confirmed and results of total RCP are in very good
agreement with the Ph.Eur. reference method. The limit of detection meets the limit
test criteria necessary to identify the total amount of impurities in a TLC QC method.
Its precision and robustness have been successfully validated. Results of the intermedi-
ate fidelity show a good correlation with the Ph.Eur. reference values, both for the
TLC-scanner and the dose calibrator measurements. This two-strip TLC method could
therefore be established for routine quality control of 99mTc-MAG3 kits by introducing
it into the SPC of the products (Package insert for Technescan MAG3. Mallinckrodt
Suisse SA, 2003; Package insert for ROTOP-MAG-3 Kit. Heider AG, 2006; Package in-
sert for Technescan MAG3. Mallinckrodt Suisse SA, 2015).
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